iCAD, INC. (NASDAQ:ICAD) Files An 8-K Unregistered Sales of Equity Securities

ME Staff 8-k
-
0

iCAD, INC. (NASDAQ:ICAD) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities

On December 20, 2018, iCAD, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “SPA”), with certain institutional and accredited investors, including, but not limited to, all of the then current directors and executive officers of the Company (the “Investors”), to which the Investors purchased unsecured subordinated convertible debentures (the “Convertible Debentures”), with an aggregate principal amount of approximately $7 million. Capitalized terms used but not defined in the following description shall have the meaning assigned to such terms in the Convertible Debentures.

As previously disclosed, on February 18, 2020, the Company notified the Investors that as of February 14, 2020, the VWAP of the Company’s common stock, par value $0.01 per share (the “Common Stock”), for each of the preceding 30 consecutive Trading Days exceeded $8.00 per share, and in accordance with the terms of the Convertible Debentures, the Company shall cause all of the Investors to convert all of the outstanding principal amount of the Convertible Debentures and the Make Whole Amount (which includes all accrued but unpaid interest through the Forced Conversion Date and all interest that would have accrued through the December 21, 2021 maturity date of the Convertible Debentures but for the conversion), into shares of the Company’s Common Stock on a Forced Conversion Date of February 21, 2020.

On the Forced Conversion Date of February 21, 2020, the Company issued to the Investors an aggregate of 1,816,089 shares of Common Stock, consisting of 1,742,500 shares issued upon conversion of the outstanding principal amount of the Convertible Debentures, and 73,589 shares, known as the Pre-Make Whole Conversion Shares, equal to the quotient of a Make Whole Amount of $697,000 (referenced above) divided by the Make Whole Conversion Rate as of February 20, 2020 ($9.26, which represents 95% of the average of the VWAPs for the 20 consecutive Trading Days ending on February 20, 2020, the Trading Day immediately prior to the Forced Conversion Date (or, for Company insiders, $12.08, which represents the closing bid price of the Common Stock on February 20, 2020)). The issuance of the Make Whole Conversion Shares shall be completed on March 20, 2020, also known as the Make Whole Issuance Date, by determining the Make Whole Conversion Rate as of March 19, 2020, by delivering any additional shares of Common Stock issuable upon the Make Whole Issuance Date (such number of shares of Common Stock to be equal to the quotient of the Make Whole Amount divided by the Make Whole Conversion Rate as of March 19, 2020, less the Pre-Make Whole Conversion Shares issued on the Forced Conversion Date).

The Convertible Debentures and the shares of Common Stock underlying the Convertible Debentures were offered and sold in a private placement exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder, and the shares of Common Stock issued upon conversion of the Convertible Debentures were issued to the conversion thereof, which is exempt from registration under the Securities Act in reliance on Section 3(a)(9) thereof.

The description of the SPA and of the Convertible Debentures are not intended to be complete and are qualified in their entirety to the form of SPA and Convertible Debentures, filed as exhibit 10.1 and 4.1, respectively, to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 27, 2018.


About iCAD, INC. (NASDAQ:ICAD)

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.